T
he two isoforms of cAMP-dependent protein kinase (PKA), PKA-I and PKA-II, share a common catalytic subunit but contain distinct regulatory (R) subunits, RI and RII, respectively (1) . Four different R subunits-RI␣, RI␤, RII␣, and RII␤-have been identified. Expression of the RI␣ subunit of PKA is increased in various human tumors and cell lines, including cancers of the breast (2-5), ovary (6, 7) , lung (8) , and colon (9) (10) (11) . Furthermore, overexpression of the RI␣ subunit of PKA correlates with malignancy and poor prognosis in cancer patients (3) (4) (5) (6) (7) . Therefore, the RI␣ subunit of PKA is a potential target for human cancer therapy. In the last decade, there have been increasing efforts to develop PKA-specific inhibitors as cancer therapeutic agents (12) (13) (14) (15) (16) (17) (18) (19) .
In the present study, we have investigated the sequencespecific effects of RI␣ antisense on global gene expression by using DNA microarray. We have used distinct antisense phosphorothioate oligonucleotides (PS-ODNs) targeted to the human RI␣ gene and the second-generation antisense ODN, which is a 2Ј-O-methyl RNA͞DNA hybrid (19) . We also examined the expression profile in cells endogenously overexpressing the RI␣ antisense gene. This system avoids the problems inherent in ODN treatment, namely, the delivery and stability of the ODN.
Methods
ODN Treatment. RI␣ antisense ODNs used were PS-ODN (15) , RNA͞DNA ODN (19) , mouse PS-ODN (15) , and appropriate control ODNs (15, 19) . Cells were treated with antisense͞control ODNs (0.2 M, 3 days) by using the cationic liposomal transfection reagent DOTAP (N- [1-(2,3-dioleoyloxy) propyl]-N,N,Ntrimethylammonium methylsulfate) (Roche Diagnostics). RNA Preparation. Total cellular RNA was prepared from control and antisense-exposed cells by using a RNeasy Midi Kit (Qiagen, Chatsworth, CA), electrophoresed, blotted onto nylon membrane, and subjected to Northern blot analysis (20) . The specific fragments of cDNA corresponding to respective genes were generated by PCR.
cDNA Microarray Analysis. Total RNA prepared from the antisense-exposed and control cells were used to synthesize 33 Plabeled cDNAs by reverse transcription. The cDNAs were hybridized to a human cDNA microarray (2,304 elements) that was primarily derived from IMAGE consortium cDNA libraries (Research Genetics, Huntsville, AL), as described (21) . Cluster analysis was performed on Z-transformed microarray data by using two separate programs available as shareware from Michael Eisen's laboratory (http:͞͞rana.lbl.gov).
Tumor Growth and Antisense Treatment. PC3 M cells (2 ϫ 10 6 cells) were inoculated s.c. into nude mice. When tumors became palpable (30-50 mg), antisense or control ODN (0.1 mg͞0.1 ml saline per mouse, daily) or saline (0.1 ml per mouse) was injected i.p. into the mice (16) . After 4 days of treatment, animals were killed, and tumors, livers, and spleens were removed, weighed, immediately frozen in liquid N 2 , and kept frozen at Ϫ80°C until used.
Results and Discussion

Parallel Expression Profiles Between Antisense ODN-Treated Cells and
Cells Overexpressing the Antisense Gene. We hypothesized that the sequence-specific effects as well as various unexpected effects of antisense might reflect previously unrecognized gene expression patterns in treated cells. We thus used DNA microarray technology (22) to identify the sequence-specific mechanism for antisense RI␣ action. We used a cDNA microarray containing 2,304 nonredundant clones to analyze gene expression patterns in cells treated with RI␣ antisense RNA͞DNA mixed backbone (19) ODN. Total RNA prepared from antisense-treated and untreated control cells was used to synthesize 33 P-labeled cDNAs, which were hybridized to cDNA microarray. Treatment of PC3 M prostate carcinoma cells with 0.2 M RI␣ antisense for 3 days inhibited growth by 50%. We compared the expression profile induced by exogenous antisense ODN treatment with that induced by the endogenous antisense gene overexpression. To address the question of cell specificity, we also analyzed the expression profiles of LS-174T colon carcinoma cells transfected with the RI␣ antisense gene.
The expression levels of Ϸ240 cDNAs, representing 10% of the total DNA elements on the array, were altered (Ն 2-fold up-regulated or down-regulated) in antisense ODN or antisense gene-treated cells. The changes ranged from Ϫ20-fold to ϩ27-fold (Table 1 (Table  1) . Less than 2% of the altered expression profiles were specific to either antisense ODN-treated cells or cells overexpressing the antisense gene ( Northern blotting confirmed the microarray data, with changes in the expression profile exerted by the antisense ODN and antisense gene (that is, the direction of changes as well as the magnitude of altered expression) (Fig. 3) . The Northern results further confirmed that the antisense RI␣ specifically downregulated PKA RI␣ mRNA without affecting the expression of other PKA subunits (Fig. 3 ).
Molecular Portrait of Reverted Phenotype of Prostate Carcinoma.
In addition to growth inhibition, RI␣ antisense treatment also induced changes in cell morphology, including a flat phenotype similar to the reverted phenotype of transformed cells (23) . To obtain a molecular portrait of the ''reverted'' phenotype, we used a hierarchical clustering algorithm to group genes on the basis of similarity in their expression patterns (24) . The data are presented in a matrix format (Fig. 4) . Each row represents all of the hybridization results for a single DNA element of the array, and each column represents the expression levels for all genes in a single hybridization sample. The expression level of each gene is visualized, in color, relative to its median expression level across all samples. Red represents expression greater than the mean, and green represents expression less than the mean, and the intensity of the color denotes the degree of deviation from the mean (24) . Distinct samples representing similar gene patterns from control cells were aligned in adjacent rows. Likewise, different samples from antisense ODN-treated or antisense gene-transfected cells were clustered in adjacent rows in our map. Also included in this map were samples from antisensetreated tumors, host livers, and various controls. The observed patterns of gene expression would thus reflect intrinsic differ- ences between antisense-exposed cells and control cells rather than variations arising from experimental artifacts. We defined clusters of coordinately expressed genes as ''signatures,'' which we named on the basis of the cellular process in which the component genes participate (25) .
Our map revealed that RI␣ antisense treatment affected a cluster of genes involved in proliferation and one involved in differentiation (Fig. 4) . Genes that define the proliferation signature were highly expressed in untreated control cells (Fig.  4E, columns 1 and 2 ) and markedly suppressed in antisensetreated or -transfected cells (Fig. 4E , Top and Middle, columns 3-6). In this proliferation signature, genes encoding proteins involved in cell cycle control, DNA synthesis and regulation, transcription, and translation were predominant. Conversely, RI␣ antisense treatment induced genes involved in differentiation and reverse transformation (Fig. 4D) . This cluster was dominated by genes encoding small G proteins, such as Cdc42 and Rap1, genes encoding transcription factors, and genes encoding regulatory proteins of the cytoskeleton, specifically the microtubules. Remarkably, the effects of RI␣ antisense treatment on these signatures were mirrored in cells overexpressing the antisense gene (Fig. 4 , compare columns 3 and 4 with 5 and 6). The altered expression signatures generated by the RI␣ antisense ODN thus reflected true antisense effects rather than nonspecific antisense ODN effects described elsewhere (26) .
Similar proliferation and differentiation signatures were observed in antisense-treated tumors (Fig. 4 D and E , Top and Middle, columns 10-12). However, we also observed an expression profile distinct from that observed in antisense-treated cells. For example, genes in the tumor-specific proliferation signature, such as those for TXK tyrosine kinase and Grb-2-associated protein, were markedly down-regulated in tumors, but unchanged in cells (Fig. 4E Bottom) . Conversely, genes in the tumor-specific differentiation signature, such as those for developmental proteins, including wingless-type mouse mammary tumor virus integration site family and sex-determining region Y were markedly up-regulated in tumors, but not in cells (Fig. 4,  legend) . Likewise, genes in the transformation signature, such as oncogenes and genes for tyrosine and serine͞threonine kinases that are usually overexpressed in tumors, were specifically down-regulated in tumors only, but not in cells, after antisense treatment (Fig. 4C) .
To verify the specificity of the antisense effects on gene expression signatures, we used three different antisense ODNs that differed in sequence or chemical modification: a PS-ODN antisense (15) , directed against codons 8-13 of human RI␣; the immunosuppressive (27) , less cytotoxic (18), second-generation RNA͞ DNA hybrid PS-ODN antisense (19) ; and a nonimmunostimula- tory 5Ј-CCG-containing (28) PS-ODN antisense (15) , targeted to codons 8-13 of mouse RI␣, that can cross hybridize with human RI␣. The immune-response signature elicited in the PS-ODN antisense-treated tumors was undetectable in the RNA͞DNA hybrid antisense-treated tumors (Fig. 4B, column 10) . The expression signatures of mouse RI␣ antisense were in close parallel with that of the RNA͞DNA hybrid antisense (Fig. 4, columns 10 and 11) , without immunostimulatory effect (Fig. 4B, column 11) . Overall, the alterations in expression signatures described above were similarly induced by all three antisense ODNs in tumors (Fig. 4,  columns 10-12 ), but not in host livers (Fig. 4, columns 13 and 14) . By contrast, the expression signatures of antisense were not elicited by control ODN (Fig. 4, column 9 ), indicating that antisense modulation of the expression signatures described above was sequence-specific. These expression signatures, together with other prominent features of the antisense-induced expression profile, appear to reflect the profile of the nonmalignant or reverted phenotype, which was shared by that observed in the host livers examined.
Conclusions
Antisense technology has been applied to specifically block disease-causing genes (29, 30) ; therefore, its use as a genespecific therapeutic agent is highly promising. Targeting of cancer genes by antisense ODNs could inhibit tumor growth. However, nonspecific side effects caused by antisense ODNs (26) have clouded the understanding of the single-gene targeting mechanism of action and hampered or delayed clinical development of antisense drugs. Our results have revealed a specific subset of genes in cancer cells that are coordinately regulated by antisense RI␣ in a sequence-specific manner. This study shows that a view of global gene expression in cancer cells exposed to antisense ODN can refine the antisense mechanism with respect to its sequence and target specificity.
Our results show that antisense acts as a multisite genomic modulator and thus goes beyond functioning as a single genetargeting agent. RI␣ antisense, once in the cell, alters the expression of hundreds of different genes, including its own target gene, and these genes can be classified into subgroups, which pinpoint specific stages of cell growth, differentiation, and transformation. Importantly, the differentiation and proliferation expression signatures were altered specifically in tumor cells; these signatures were quiescent and unaltered in the host livers of antisense-treated animals.
In this differentiation signature, the genes showing the highest induction included genes for Rap1A and Cdc42, small G proteins with GTPase activity. Both Rap1A and Cdc42 are multifunctional proteins related to both cell proliferation and differentiation (31) . However, the RI␣ antisense induction of these G proteins in cancer cells occurred concomitantly with the induction of other proteins involved in differentiation and with the down-regulation of a cluster of genes involved in cell proliferation and transformation. Thus, in this case, the induction of these G proteins appears to promote differentiation and reverse transformation rather than proliferation and transformation in cancer cells.
Although we know that RI␣ antisense behaves as a multisite genomic modulator, its precise molecular mechanism of action is still unknown. We speculate that cAMP response elementdirected transcription (32) , which is triggered by the activation of PKA via antisense depletion of RI␣ (19) , may play a central role in this process.
Gene expression profiling presents a way of refining cancer chemotherapeutics in the future. Revisiting antisense-targeted gene expression on a genomic scale will facilitate the discovery of clinically appropriate antisense drugs as well as providing a unique perspective on the development of new chemotherapeutic combinations based on the molecular actions of these drugs.
